Table of Content

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.2.1 INCLUSIONS & EXCLUSIONS 20
1.2.2 MARKETS COVERED 20
FIGURE 1 PRIMARY CELLS MARKET 20
1.2.3 YEARS CONSIDERED FOR THE STUDY 21
1.3 CURRENCY 21
1.4 LIMITATIONS 21
1.5 STAKEHOLDERS 21
1.6 REPORT COMPARISON WITH THE JULY 2018 EDITION 22
1.6.1 SUMMARY OF CHANGES 22
1.6.2 LIMITATIONS OF THE CURRENT EDITION 22

2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.2 RESEARCH APPROACH 23
FIGURE 2 PRIMARY CELLS MARKET: RESEARCH DESIGN 23
2.2.1 SECONDARY DATA 24
2.2.1.1 Key data from secondary sources 24
2.2.2 PRIMARY DATA 25
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25
2.2.2.1 Key data from primary sources 26
2.3 MARKET SIZE ESTIMATION 26
2.3.1 BOTTOM-UP APPROACH 27
FIGURE 4 PRIMARY CELLS MARKET: BOTTOM-UP APPROACH 27
2.3.2 TOP-DOWN APPROACH 28
FIGURE 5 PRIMARY CELLS MARKET: TOP-DOWN APPROACH 28
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 29
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
2.5 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31
FIGURE 7 PRIMARY CELLS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION) 31
FIGURE 8 PRIMARY CELLS MARKET, BY ORIGIN, 2020 VS. 2025 (USD MILLION) 32
FIGURE 9 PRIMARY CELLS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION) 32
FIGURE 10 PRIMARY CELLS MARKET, BY REGION, 2020 VS. 2025 (USD MILLION) 33
?

4 PREMIUM INSIGHTS 34
4.1 PRIMARY CELLS MARKET OVERVIEW 34
FIGURE 11 INCREASING CANCER RESEARCH IS DRIVING THE GROWTH OF THE PRIMARY CELLS MARKET 34
4.2 PRIMARY CELLS MARKET, BY ORIGIN, 2020 VS. 2025 (USD MILLION) 35
FIGURE 12 HUMAN PRIMARY CELLS SEGMENT TO DOMINATE THE MARKET IN 2020 35
4.3 PRIMARY CELLS MARKET SHARE, BY END USER, 2020 VS. 2025 (USD MILLION) 35
FIGURE 13 LIFE SCIENCE RESEARCH COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE PRIMARY CELLS MARKET DURING THE FORECAST PERIOD 35
4.4 PRIMARY CELLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 36
FIGURE 14 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE PRIMARY CELLS MARKET DURING THE FORECAST PERIOD 36

5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
FIGURE 15 PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 37
5.2.1 DRIVERS 37
5.2.1.1 Increasing cancer research 37
TABLE 1 PROJECTED INCREASE IN THE NUMBER OF CANCER PATIENTS,
2015 VS. 2018 VS. 2035 38
TABLE 2 RESEARCH FUNDING FOR NATIONAL CANCER INSTITUTE,
2015 VS. 2017 (USD MILLION) 38
5.2.1.2 Advantages of primary human cells over cell lines 39
5.2.1.3 Increasing demand for monoclonal antibodies 39
5.2.1.4 Rapid growth in the biotechnology and biopharmaceutical industries 39
FIGURE 16 GLOBAL PHARMACEUTICAL & BIOPHARMACEUTICAL
R&D EXPENDITURE, 2017–2024 40
5.2.1.5 Growing focus on personalized medicine 40
TABLE 3 GROWTH IN THE NUMBER OF PERSONALIZED MEDICATIONS, 2008–2016 40
5.2.1.6 Government investments for cell-based research 41
5.2.2 RESTRAINTS 42
5.2.2.1 Concerns regarding primary cell culture contamination 42
5.2.2.2 Ethical concerns regarding research in cell biology 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 Advancing biomedical research using primary cells in 3D cultures 42
5.3 COVID-19 IMPACT ON THE PRIMARY CELLS MARKET 43
5.4 PRICING ANALYSIS 44
TABLE 4 PRICE OF PRIMARY CELLS (2020) 44
5.5 VALUE CHAIN ANALYSIS 46
FIGURE 17 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE 47
5.6 SUPPLY CHAIN ANALYSIS 47
FIGURE 18 DISTRIBUTION?A STRATEGY PREFERRED BY PROMINENT COMPANIES 48
5.7 ECOSYSTEM ANALYSIS OF THE PRIMARY CELLS MARKET 49
FIGURE 19 ECOSYSTEM ANALYSIS OF THE PRIMARY CELLS MARKET 49

6 PRIMARY CELLS MARKET, BY ORIGIN 50
6.1 INTRODUCTION 51
TABLE 5 PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 51
6.2 HUMAN PRIMARY CELLS 51
6.2.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH 51
TABLE 6 HUMAN PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 52
6.3 ANIMAL PRIMARY CELLS 53
6.3.1 RISING INVESTMENTS IN ANIMAL CELL RESEARCH TO PROPEL
THE MARKET GROWTH 53
TABLE 7 ANIMAL PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 53

7 PRIMARY CELLS MARKET, BY TYPE 54
7.1 INTRODUCTION 55
TABLE 8 PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 55
7.2 HEMATOPOIETIC CELLS 56
7.2.1 INCREASING CANCER RESEARCH & FUNDING TO PROPEL
THE MARKET GROWTH 56
TABLE 9 HEMATOPOIETIC CELLS, BY TYPE 56
TABLE 10 HEMATOPOIETIC CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 57
TABLE 11 NORTH AMERICA: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 57
TABLE 12 EUROPE: HEMATOPOIETIC CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 57
TABLE 13 ASIA PACIFIC: HEMATOPOIETIC CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 58
7.3 DERMATOCYTES 58
7.3.1 RISING PREVALENCE OF MELANOMA IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT 58
TABLE 14 DERMATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION) 59
TABLE 15 NORTH AMERICA: DERMATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 59
TABLE 16 EUROPE: DERMATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 59
TABLE 17 ASIA PACIFIC: DERMATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 60
7.4 GASTROINTESTINAL CELLS 60
7.4.1 INCREASING INCIDENCE OF STOMACH CANCER TO BOLSTER MARKET GROWTH 60
TABLE 18 GASTROINTESTINAL CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 60
TABLE 19 NORTH AMERICA: GASTROINTESTINAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 61
TABLE 20 EUROPE: GASTROINTESTINAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 61
TABLE 21 ASIA PACIFIC: PRIMARY GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 61
7.5 HEPATOCYTES 62
TABLE 22 GLOBAL LIVER DISORDER INCIDENCE 62
TABLE 23 HEPATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION) 63
TABLE 24 HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 63
TABLE 25 NORTH AMERICA: HEPATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 64
TABLE 26 EUROPE: HEPATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 64
TABLE 27 ASIA PACIFIC: HEPATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 64
7.5.1 CRYOPRESERVED HEPATOCYTES 65
7.5.1.1 Longer lifespan of cryopreserved hepatocytes than fresh hepatocytes to drive market growth 65
TABLE 28 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION,
2018–2025 (USD MILLION) 65
7.5.2 FRESH HEPATOCYTES 65
7.5.2.1 Stringent regulations and limited availability of fresh hepatocytes to limit market growth 65
TABLE 29 FRESH HEPATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION) 66
7.6 LUNG CELLS 66
7.6.1 INCREASING RATE OF LUNG CANCER & COPD TO DRIVE THE DEMAND FOR LUNG CELLS 66
TABLE 30 LUNG CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 67
TABLE 31 NORTH AMERICA: LUNG CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 67
TABLE 32 EUROPE: LUNG CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 68
TABLE 33 ASIA PACIFIC: LUNG CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 68
7.7 RENAL CELLS 68
7.7.1 LACK OF AVAILABILITY OF EFFECTIVE RENAL THERAPIES TO
PROPEL MARKET GROWTH 68
TABLE 34 RENAL CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 69
TABLE 35 NORTH AMERICA: RENAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 69
TABLE 36 EUROPE: RENAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 69
TABLE 37 ASIA PACIFIC: RENAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 70
7.8 HEART CELLS 70
7.8.1 HIGH INCIDENCE OF CARDIOVASCULAR DISEASES IS SUPPORTING THE GROWTH OF THIS SEGMENT 70
TABLE 38 HEART CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 70
TABLE 39 NORTH AMERICA: HEART CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 71
TABLE 40 EUROPE: HEART CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 71
TABLE 41 ASIA PACIFIC: HEART CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 71
7.9 MUSCULOSKELETAL CELLS 72
7.9.1 RISING INCIDENCE OF MUSCULOSKELETAL DISORDERS TO PROPEL MARKET GROWTH 72
TABLE 42 MUSCULOSKELETAL CELLS MARKET, BY REGION,
2018–2025 (USD MILLION) 72
TABLE 43 NORTH AMERICA: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 72
TABLE 44 EUROPE: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 73
TABLE 45 ASIA PACIFIC: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 73
7.10 OTHER PRIMARY CELLS 73
TABLE 46 OTHER PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 74
TABLE 47 NORTH AMERICA: OTHER PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 74
TABLE 48 EUROPE: OTHER PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 74
TABLE 49 ASIA PACIFIC: OTHER PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 75

8 PRIMARY CELLS MARKET, BY END USER 76
8.1 INTRODUCTION 77
TABLE 50 PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 77
8.2 LIFE SCIENCE RESEARCH COMPANIES 77
8.2.1 INCREASING INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE THE MARKET GROWTH 77
TABLE 51 PRIMARY CELLS MARKET FOR LIFE SCIENCE RESEARCH COMPANIES,
BY REGION, 2018–2025 (USD MILLION) 78
8.3 RESEARCH INSTITUTES 78
8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH AND HIGH PREVALENCE OF CANCER ARE DRIVING MARKET GROWTH 78
TABLE 52 PRIMARY CELLS MARKET FOR RESEARCH INSTITUTES, BY REGION,
2018–2025 (USD MILLION) 79

9 PRIMARY CELLS MARKET, BY REGION 80
9.1 INTRODUCTION 81
TABLE 53 PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 81
9.2 NORTH AMERICA 81
FIGURE 20 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 82
FIGURE 21 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT 83
TABLE 54 NORTH AMERICA: PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 84
TABLE 55 NORTH AMERICA: PRIMARY CELLS MARKET, BY ORIGIN,
2018–2025 (USD MILLION) 84
TABLE 56 NORTH AMERICA: PRIMARY CELLS MARKET, BY TYPE,
2018–2025 (USD MILLION) 84
TABLE 57 NORTH AMERICA: HEPATOCYTES MARKET, BY TYPE,
2018–2025 (USD MILLION) 85
TABLE 58 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 85
9.2.1 US 85
9.2.1.1 High R&D spending and growing support for stem cell research to drive market growth in the US 85
FIGURE 22 US: CANCER INCIDENCE & MORTALITY, 2012–2035 86
TABLE 59 US: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 86
TABLE 60 US: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 87
TABLE 61 US: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 87
TABLE 62 US: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 87
9.2.2 CANADA 88
9.2.2.1 Presence of advanced R&D infrastructure to drive market growth 88
TABLE 63 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 88
TABLE 64 CANADA: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 89
TABLE 65 CANADA: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 89
9.3 EUROPE 89
FIGURE 23 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 90
TABLE 66 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 90
TABLE 67 EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 90
TABLE 68 EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 69 EUROPE: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 70 EUROPE: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 91
9.3.1 UK 92
9.3.1.1 Growth in the life sciences industry to drive market growth in the UK 92
TABLE 71 UK: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 92
TABLE 72 UK: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 73 UK: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 93
9.3.2 GERMANY 93
9.3.2.1 Increasing life science research activities to support market growth 93
TABLE 74 GERMANY: PRIMARY CELLS MARKET, BY ORIGIN,
2018–2025 (USD MILLION) 94
TABLE 75 GERMANY: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 94
TABLE 76 GERMANY: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 95
9.3.3 FRANCE 95
9.3.3.1 Robust biotechnology infrastructure in the country to support market growth 95
TABLE 77 FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 95
TABLE 78 FRANCE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 79 FRANCE: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 96
9.3.4 ITALY 96
9.3.4.1 Increasing number of cell biology seminars and conferences to fuel the adoption of primary cells 96
TABLE 80 ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 97
TABLE 81 ITALY: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 82 ITALY: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 98
9.3.5 REST OF EUROPE 98
TABLE 83 ROE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 98
TABLE 84 ROE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 85 ROE: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 99
9.4 ASIA PACIFIC 100
FIGURE 24 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 100
FIGURE 25 ASIA PACIFIC: PRIMARY CELLS MARKET SNAPSHOT 101
TABLE 86 APAC: PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 102
TABLE 87 APAC: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 102
TABLE 88 APAC: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 89 APAC: HEPATOCYTES, BY TYPE, 2018–2025 (USD MILLION) 103
TABLE 90 APAC: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 103
9.4.1 CHINA 103
9.4.1.1 Growing focus on cancer therapeutics-related research to bolster market growth 103
TABLE 91 CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 104
TABLE 92 CHINA: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 93 CHINA: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 105
9.4.2 JAPAN 105
9.4.2.1 Government initiatives to propel market growth in Japan 105
TABLE 94 JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 105
TABLE 95 JAPAN: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 106
TABLE 96 JAPAN: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 106
9.4.3 REST OF ASIA PACIFIC 106
TABLE 97 ROAPAC: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 107
TABLE 98 ROAPAC: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
TABLE 99 ROAPAC: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 107
9.5 REST OF THE WORLD 108
TABLE 100 ROW: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 108
TABLE 101 ROW: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 102 ROW: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 103 ROW: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 109

10 COMPETITIVE LANDSCAPE 110
10.1 OVERVIEW 110
FIGURE 26 KEY DEVELOPMENTS IN THE PRIMARY CELLS MARKET (2017 TO 2020) 110
10.2 MARKET SHARE ANALYSIS 111
FIGURE 27 PRIMARY CELLS MARKET SHARE, BY KEY PLAYER (2019) 111
10.3 COMPETITIVE SCENARIO 112
10.3.1 PRODUCT LAUNCHES 112
TABLE 104 PRODUCT LAUNCHES 112
10.3.2 AGREEMENTS 113
TABLE 105 AGREEMENTS 113
10.3.3 EXPANSIONS 113
TABLE 106 EXPANSIONS 113
10.3.4 PARTNERSHIPS 114
TABLE 107 PARTNERSHIPS 114
10.3.5 ACQUISITIONS 115
TABLE 108 ACQUISITIONS 115
11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 116
11.1 COMPANY EVALUATION MATRIX DEFINITIONS AND METHODOLOGY 116
11.1.1 VENDOR EXCLUSION CRITERIA 116
11.1.2 STARS 116
11.1.3 EMERGING LEADERS 116
11.1.4 PERVASIVE PLAYERS 116
11.1.5 PARTICIPANTS 116
FIGURE 28 PRIMARY CELLS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 117
11.2 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2019) 117
11.2.1 PROGRESSIVE COMPANIES 117
11.2.2 STARTING BLOCKS 118
11.2.3 RESPONSIVE COMPANIES 118
11.2.4 DYNAMIC COMPANIES 118
FIGURE 29 PRIMARY CELLS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019 118
11.3 COMPANY PROFILES 119
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.3.1 THERMO FISHER SCIENTIFIC, INC. 119
FIGURE 30 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019) 119
11.3.2 MERCK KGAA 122
FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2019) 122
11.3.3 LONZA 127
FIGURE 32 LONZA: COMPANY SNAPSHOT (2019) 127
11.3.4 PROMOCELL GMBH 130
11.3.5 CORNING INCORPORATED 132
FIGURE 33 CORNING INCORPORATED: COMPANY SNAPSHOT (2019) 132
11.3.6 AMERICAN TYPE CULTURE COLLECTION (ATCC) 134
11.3.7 CELL BIOLOGICS, INC. 136
11.3.8 HEMACARE CORPORATION (A CHARLES RIVER LABORATORIES, INC. COMPANY) 140
FIGURE 34 CHARLES RIVER LABORATORIES, INC.: COMPANY SNAPSHOT (2019) 140
11.3.9 ZENBIO, INC. 143
11.3.10 STEM CELL TECHNOLOGIES, INC. 144
11.3.11 ALLCELLS 146
11.3.12 AXOL BIOSCIENCE LTD. 147
11.3.13 IXCELLS BIOTECHNOLOGIES 150
11.3.14 NEUROMICS 155
11.3.15 STEMEXPRESS 157
11.3.16 BIOIVT 159
11.3.17 SCIENCELL RESEARCH LABORATORIES, INC. 163
11.3.18 SEKISUI XENOTECH, LLC 165
11.3.19 PPA RESEARCH GROUP, INC. 167
11.3.20 CREATIVE BIOARRAY 168
11.3.21 BPS BIOSCIENCE, INC. 170
11.3.22 EPITHELIX S?RL 170
11.3.23 REACHBIO LLC 171
11.3.24 ACCEGEN 171
11.3.25 BIOPREDIC INTERNATIONAL 172
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 173
12.1 INSIGHTS FROM INDUSTRY EXPERTS 173
12.2 DISCUSSION GUIDE 174
12.3 KNOWLEDGE STORE 176
12.4 AVAILABLE CUSTOMIZATIONS 178
12.5 RELATED REPORTS 178
12.6 AUTHOR DETAILS 179